MX2015001685A - Combinaciones con un peptido con esqueleto ciclado. - Google Patents

Combinaciones con un peptido con esqueleto ciclado.

Info

Publication number
MX2015001685A
MX2015001685A MX2015001685A MX2015001685A MX2015001685A MX 2015001685 A MX2015001685 A MX 2015001685A MX 2015001685 A MX2015001685 A MX 2015001685A MX 2015001685 A MX2015001685 A MX 2015001685A MX 2015001685 A MX2015001685 A MX 2015001685A
Authority
MX
Mexico
Prior art keywords
dab
diseases
infections
trp
backbone
Prior art date
Application number
MX2015001685A
Other languages
English (en)
Other versions
MX366997B (es
Inventor
Glenn E Dale
Daniel Obrecht
Francesca Bernardini
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MX2015001685A publication Critical patent/MX2015001685A/es
Publication of MX366997B publication Critical patent/MX366997B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una combinación novedosa que comprende un peptidomimético de ß-horquilla de la fórmula ciclo(Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-D ab-Dab-Ala-Ser-DPro-Pro) (I), y un compuesto de la clase de glicilciclina, especialmente tigeciclina, que permite el control terapéutico de infecciones bacterianas específicas en humanos o animales a dosis de los compuestos individuales menores que cualquiera de los compuestos administrados solos. La combinación se puede usar como un medicamento para tratar, v.gr., infecciones de la piel o tejido blando; infecciones de los ojos, oídos, torrente sanguíneo o intra-abdominales; infecciones relacionadas con enfermedades respiratorias, enfermedades de los huesos, enfermedades cardiovasculares, enfermedades genitourinarias o enfermedades gastrointestinales.
MX2015001685A 2012-08-08 2013-08-07 Combinaciones con un peptido con esqueleto ciclado. MX366997B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12005744 2012-08-08
PCT/EP2013/066530 WO2014023757A1 (en) 2012-08-08 2013-08-07 Combinations with a backbone-cyclized peptide

Publications (2)

Publication Number Publication Date
MX2015001685A true MX2015001685A (es) 2015-04-10
MX366997B MX366997B (es) 2019-08-02

Family

ID=46796226

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015001685A MX366997B (es) 2012-08-08 2013-08-07 Combinaciones con un peptido con esqueleto ciclado.
MX2019002657A MX2019002657A (es) 2012-08-08 2015-02-06 Combinaciones con un peptido con esqueleto ciclado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019002657A MX2019002657A (es) 2012-08-08 2015-02-06 Combinaciones con un peptido con esqueleto ciclado.

Country Status (26)

Country Link
US (1) US9775877B2 (es)
EP (1) EP2882770B1 (es)
JP (2) JP6486270B2 (es)
KR (1) KR102167324B1 (es)
CN (1) CN104684925B (es)
AU (1) AU2013301567B2 (es)
BR (1) BR112015002727B1 (es)
CA (1) CA2879207C (es)
CY (1) CY1119308T1 (es)
DK (1) DK2882770T3 (es)
EA (1) EA030077B1 (es)
ES (1) ES2639165T3 (es)
HK (1) HK1207866A1 (es)
HR (1) HRP20171299T1 (es)
HU (1) HUE035891T2 (es)
IL (1) IL236697B (es)
LT (1) LT2882770T (es)
MX (2) MX366997B (es)
NZ (1) NZ703729A (es)
PL (1) PL2882770T3 (es)
PT (1) PT2882770T (es)
RS (1) RS56249B1 (es)
SG (1) SG11201500216TA (es)
SI (1) SI2882770T1 (es)
WO (1) WO2014023757A1 (es)
ZA (1) ZA201500278B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104090A1 (en) 2007-02-28 2008-09-04 Polyphor Ag Template-fixed peptidomimetics
ES2639165T3 (es) * 2012-08-08 2017-10-25 Polyphor Ag Combinaciones con un péptido de esqueleto ciclado
IL303021A (en) * 2020-11-23 2023-07-01 Spexis Ag Peptidomimetic beta-herpain compositions and spray dosage forms thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070547A1 (en) 2001-02-23 2002-09-12 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
AU2002342618C1 (en) 2002-08-20 2008-10-30 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
WO2007079597A1 (en) * 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
WO2008104090A1 (en) * 2007-02-28 2008-09-04 Polyphor Ag Template-fixed peptidomimetics
US20100035845A1 (en) * 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
ES2639165T3 (es) * 2012-08-08 2017-10-25 Polyphor Ag Combinaciones con un péptido de esqueleto ciclado

Also Published As

Publication number Publication date
US9775877B2 (en) 2017-10-03
EP2882770B1 (en) 2017-05-31
NZ703729A (en) 2018-03-23
EA030077B1 (ru) 2018-06-29
PT2882770T (pt) 2017-09-11
CY1119308T1 (el) 2018-02-14
IL236697B (en) 2020-02-27
HRP20171299T1 (hr) 2017-10-20
BR112015002727B1 (pt) 2022-09-06
ES2639165T3 (es) 2017-10-25
JP6486270B2 (ja) 2019-03-20
HUE035891T2 (en) 2018-05-28
CN104684925A (zh) 2015-06-03
AU2013301567A1 (en) 2015-02-05
WO2014023757A1 (en) 2014-02-13
CN104684925B (zh) 2021-11-30
LT2882770T (lt) 2017-10-10
US20150216927A1 (en) 2015-08-06
CA2879207A1 (en) 2014-02-13
EP2882770A1 (en) 2015-06-17
MX2019002657A (es) 2019-07-15
KR20150038612A (ko) 2015-04-08
IL236697A0 (en) 2015-02-26
DK2882770T3 (en) 2017-09-18
EA201590351A1 (ru) 2016-05-31
HK1207866A1 (en) 2016-02-12
SI2882770T1 (sl) 2017-10-30
PL2882770T3 (pl) 2018-01-31
ZA201500278B (en) 2016-01-27
KR102167324B1 (ko) 2020-10-20
MX366997B (es) 2019-08-02
JP2018087191A (ja) 2018-06-07
RS56249B1 (sr) 2017-11-30
JP2015524460A (ja) 2015-08-24
SG11201500216TA (en) 2015-03-30
AU2013301567B2 (en) 2017-08-03
CA2879207C (en) 2021-02-16
BR112015002727A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
UA104320C2 (ru) Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
NZ701607A (en) Therapeutic use of chardonnay seed products
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX2011008616A (es) Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
IN2012DN06720A (es)
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
NZ604662A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
NZ605841A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
ATE553772T1 (de) Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
MX2019002657A (es) Combinaciones con un peptido con esqueleto ciclado.
EP2545929A4 (en) ENHANCING OR TREATING AGENT FOR CHRONIC PROSTATITIS, INTERSTITIAL CYSTITIS AND / OR MICTION DISORDERS
MX2019002894A (es) Combinaciones con un peptido ciclado con la estructura de la base.
EP3590338A3 (en) Medical treatments based on anamorelin
IN2014CN03333A (es)
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
EA201791895A1 (ru) Дозы и способы введения телаванцина
MY170190A (en) Use of a fermented soy extract as a prebiotic composition

Legal Events

Date Code Title Description
FG Grant or registration